Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974269 | 0.95 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4967008 | 0.93 | ALDH1A1 (0.40) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3836004 | 0.87 | ALDH1A1 (0.49) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9718366 | 0.81 | CYP3A4 (0.45) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2139882 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4492753 | 0.79 | TYMP (0.36) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5624068 | 0.79 | TYMP (0.36) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15827375 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5141135 | 0.77 | KDM4E (0.44) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL1627565 | 0.77 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5084201-A | Soluble copper amino alkoxides | AKZO N.V. (NL) | 1992-01-28 | — | — | US | claimed |
| EP-0442563-A2 | Soluble heavy metal amino alkoxides | AKZO N.V. (NL) | 1991-08-21 | — | — | EP | claimed |
| JP-60228472-A | — | — | None | — | — | JP | disclosed |
| JP-4270292-A | — | — | None | — | — | JP | disclosed |
| US-20260070069-A1 | PURIFICATION OF MINERAL ORES USING CATIONIC COPOLYMERS | ECOLAB USA INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-10858474-B2 | Reactive polyurethane dispersions | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10857825-B2 | Inkjet printing | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10821760-B2 | Inkjet printing | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10723897-B2 | Inkjet compositions | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723896-B2 | Inkjet printing | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190352519-A1 | INKJET COMPOSITIONS | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2019-11-21 | — | — | US | disclosed |
| US-6287591-B1 | STABLE FOR THERAPUTIC USE, HIV, CYTOMEGALO VIRUS, ANTIINFLAMMATORY, ANTITUMOR | INEX PHARMACEUTICALS CORP. (CA) | 2001-09-11 | — | — | US | disclosed |
| EP-1027033-A2 | HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES | Inex Pharmaceuticals Corp. (CA) | 2000-08-16 | — | — | EP | disclosed |
| US-6075012-A | TRANSFECTION | LIFE TECHNOLOGIES, INC. (US) | 2000-06-13 | — | — | US | disclosed |
| WO-1998051278-A2 | HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES | INEX PHARMACEUTICALS CORPORATION (CA) | 1998-11-19 | — | — | WO | disclosed |
| US-5534499-A | Lipophilic drug derivatives for use in liposomes | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1996-07-09 | — | — | US | disclosed |
| JP-H04270292-A | SOLUBLE HEAVY METAL AMINO ALKOXIDE | AKZO NV | 1992-09-25 | — | — | JP | disclosed |
| US-5084201-A | Soluble copper amino alkoxides | AKZO N.V. (NL) | 1992-01-28 | — | — | US | disclosed |
| EP-0442563-A2 | Soluble heavy metal amino alkoxides | AKZO N.V. (NL) | 1991-08-21 | — | — | EP | disclosed |
| JP-S60228472-A | NOVEL POLYMERIZABLE MONOMER AND PREPARATION THEREOF | NEOS CO LTD | 1985-11-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070069-A1 | PURIFICATION OF MINERAL ORES USING CATIONIC COPOLYMERS | AS3MT, SAMM50, ADCY10 | ALDH1A1 1825/4885TSHR 822/4885CYP1A2 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.